A diversified portfolio of biotherapy companies
Our companies are where cutting-edge research becomes real-world therapies. Each portfolio company advances a distinct scientific strategy, supported by Remora’s expertise in bioengineering, biological drug design, technology development, and company building.
Activen
Miniprotein™ actives
A Remora Biotech Company
Market: Cosmetics
Segment: Regenerative anti-age
Commercialized
Fastox Pharma (exit)
Botulinum neurotoxin booster
A Remora Biotech Company
Market: Aesthetics & neurology
Segment: Botox®
Acquired by AbbVie in 2024
Atlab Pharma (exit)
Antibody-targeted beta-therapy
A Remora Biotech Company
Market: Radiopharmaceuticals
Segment: Prostate cancer
Acquired by Telix in 2018
Cytune Pharma (exit)
Cytokine
A Remora Biotech Company
Market: Immunotherapy
Segment: Cancer
Acquired by SOTIO in 2018
OGD2 Pharma
Innovative cancer target
A Remora Biotech Company
Market: Immunotherapy
Segment: Pediatric cancer
Cellula Therapeutics
mRNA CAR-T cells
A Remora Biotech Company
Market: Cell therapy
Segment: Brain cancer
iMoon Therapeutics
Targeted cytokines
A Remora Biotech Company
Market: Immunotherapy
Segment: Cancer
Nanomunity
Multi-checkpoint inhibitors
A Remora Biotech Company
Market: Immunotherapy
Segment: Cancer
Radiomune Pharma
Targeted alpha-therapy
A Remora Biotech Company
Market: Radiopharmaceuticals
Segment: Cancer
Kalsiom
Innovative auto-reactive target
A Remora Biotech Company
Market: Immunotherapy
Segment: Autoimmunity
The MiniproteinTM Lab
Miniprotein™ formulations
A Remora Biotech Company
Market: Cosmetics
Segment: Regenerative anti-age
Atonco
Antibody-targeted alpha-therapy
Strategic Minority Investment
Market: Radiopharmaceuticals
Segment: Bladder cancer
Byome Labs
Microbiota profiling
Strategic Minority Investment
Market: Cosmetics
Segment: Point-of-care diagnostics